Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership
ALK Positive Inc. (ALK Positive) announces a new partnership with Break Through Cancer, to join forces in funding a new initiative in lung cancer research with the hope of creating durable responses and cures for ALK-positive lung cancer patients.
Why fund ALK-positive lung cancer research?
Since the discovery of ALK Non-Small Cell Lung Cancer (NSCLC) in 2007, the landscape of cancer treatment has undergone a remarkable transformation. Breakthroughs in research have not only extended lives but have also minimized the burden of side effects. Oral medications like ALK tyrosine kinase inhibitors (TKIs) have been pivotal, often leading to profound responses with minimal residual disease detectable by scanning. Unfortunately, tumor resistance to these TKIs increase and the minimal residual disease, of which 97% of ALK-patients live with, fuels the cancer’s recurrence, and spread; leaving little to no options for treatment.
At ALK Positive, we have been at the forefront of driving medical advancements. Our commitment to innovation and collaboration has propelled us towards a future where ALK-positive lung cancer is not just treatable but manageable. This journey towards transformative change has brought us to a pivotal moment, where breakthrough research and cutting-edge technologies hold the promise of turning the tide against this disease.
In our relentless pursuit of progress, we've joined forces with Break Through Cancer, an esteemed foundation dedicated to empowering researchers and physicians in their quest to intercept and cure some of the world's deadliest cancers. Through radical collaboration, we're pooling our resources, expertise, and determination to significantly extend treatment responses for patients with ALK-positive lung cancer, in hopes to find a cure.
Together, let's rewrite the future of cancer treatment. Your contribution will fuel our mission, enabling us to sponsor crucial clinical trials, foster collaboration among top minds in cancer research, and drive innovation that will redefine the landscape of cancer treatment. Join us in our quest to create a world without ALK-positive cancers. Together, we can turn the promise of breakthroughs into a reality.